Akeso lung cancer drug shines in trials, boosting hopes in US$20b marketIvonescimab phase three trials reduce death risk by 34 per cent, as analysts predict it could transform non-small cell lung cancer therapy2-MIN READ2-MIN1ListenPublished: 6:49pm, 1 Jun 2026Akeso, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses.Analysts suggest it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and have revised their target prices upwards.The drug’s phase three trial found that ivonescimab reduced the risk of death by 34 per cent, according to a filing with the Hong Kong stock exchange on Monday.Select VoiceSelect Speed0.8x0.9x1.0x1.1x1.2x1.5x1.75x00:0000:001.00x
SRCSouth China Morning Post
LANGEN
LEANCenter-Right
WORDS128
ENT5
MON · 2026-06-01 · 10:49 GMTBRIEF NSR-2026-0601-80831
NSR-2026-0601-80831News Report·EN·Public Health
Akeso lung cancer drug shines in trials, boosting hopes in US$20b market
Akeso has announced positive phase three clinical trial results for its lung cancer drug, ivonescimab. The drug demonstrated a 34% reduction in the risk of death for patients with a type of lung cancer common in smokers.
Julie ZhangSouth China Morning PostFiled 2026-06-01 · 10:49 GMTLean · Center-RightRead · 1 min
South China Morning PostFIG 01
Reading time
1min
Word count
128words
Sources cited
1cited
Entities identified
5entities
Quality score
100%
§ 01
Briefing Summary
AI-generatedNEWSAR · AI
Akeso has announced positive phase three clinical trial results for its lung cancer drug, ivonescimab. The drug demonstrated a 34% reduction in the risk of death for patients with a type of lung cancer common in smokers. Analysts anticipate that ivonescimab could become a significant therapy within the US$20 billion global non-small cell lung cancer market, leading to upward revisions of target prices. These findings potentially expand the drug's approved uses and offer new hope in treating this disease.
Confidence 0.85Sources 1Claims 4Entities 5
§ 02
Article analysis
Model · rule-basedFraming
Public Health
Economic Impact
Tone
Measured
AI-assessed
CalmNeutralAlarmist
Factuality
0.70 / 1.00
Factual
LowHigh
Sources cited
1
Limited
FewMany
§ 03
Key claims
4 extracted01
Ivonescimab phase three trials reduced the risk of death by 34 per cent.
statisticAkeso
Confidence
0.90
02
Akeso's drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year.
quotearticle
Confidence
0.80
03
Ivonescimab could become a backbone therapy in the US$20 billion global non-small cell lung cancer market.
predictionanalysts
Confidence
0.70
04
Ivonescimab could transform non-small cell lung cancer therapy.
predictionanalysts
Confidence
0.70
§ 04
Full report
1 min read · 128 words§ 05
Entities
5 identifiedKey playerOppositionContextPositiveNeutralNegative
Organizations1
Locations1
§ 06
Keywords & salience
8 termsivonescimab
1.00
lung cancer
1.00
clinical trials
0.90
non-small cell lung cancer
0.80
death risk
0.70
biotech
0.60
therapy
0.50
market
0.40
§ 07
Topic connections
Interactive graph No topic relationship data available yet. This graph will appear once topic relationships have been computed.